Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. Katlama, Christine; Assoumou, Lambert; Valantin, Marc-Antoine; Soulié, Cathia; Martinez, Esteban; Béniguel, Lydie; Bouchaud, Olivier; Raffi, François; Molina, Jean-Michel; Fellahi, Soraya; Peytavin, Gilles; Marcelin, Anne-Geneviève; Kolta, Sami; Capeau, Jacqueline; Gibowski, Severine; Cardon, Fanny; Reynes, Jacques; Costagliola, Dominique; members of the ANRS 163 ETRAL study. The Journal of Antimicrobial Chemotherapy. 2019; 74: p.2742-2751. doi:10.1093/jac/dkz224
Article